SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 93.20 |
| Enterprise Value ($M) | 70.36 |
| Book Value ($M) | 51.85 |
| Book Value / Share | 0.48 |
| Price / Book | 1.80 |
| NCAV ($M) | -38.48 |
| NCAV / Share | -0.36 |
| Price / NCAV | -2.42 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.88 |
| Return on Assets (ROA) | -0.66 |
| Return on Equity (ROE) | -0.98 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.20 |
| Current Ratio | 3.20 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 87.44 |
| Assets | 177.77 |
| Liabilities | 125.92 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 16.34 |
| Operating Income | -139.62 |
| Net Income | -138.49 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -121.65 |
| Cash from Investing | 102.34 |
| Cash from Financing | 25.12 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Redmile Group, LLC | 9.90 | 19.47 | |
| 13G/A | Point72 Asset Management, L.P. | 4.20 | -48.40 | |
| 13G/A | Frazier Life Sciences Public Fund, L.P. | 1.10 | -79.09 | |
| 13G | Morgan Stanley | 5.80 | ||
| 13G | BlackRock Inc. | 6.20 | 206.62 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| wa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
| wa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,352,322 | 4,199,954 | 32.20 | |
| 460,208 | 567,884 | 81.04 | |
| 776,246 | 418,083 | 185.67 | |
| 306,258 | 206,264 | 148.48 | |
| 320,909 | 147,729 | 217.23 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GILD – Gilead Sciences, Inc. | GLUE – Monte Rosa Therapeutics, Inc. |
| GOSS – Gossamer Bio, Inc. | GTHX – G1 Therapeutics, Inc. |
| HALO – Halozyme Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io